1. Clinical Overview of Larazotide

Molecule: Larazotide Acetate (AT-1001) · Class: Tight Junction Regulator / Zonulin Pathway Antagonist / Anti-inflammatory Peptide

Clinical Orientation: Larazotide is an orally active peptide that regulates tight junctions in the gastrointestinal epithelium. Initially developed for celiac disease, it has broad clinical relevance for conditions characterized by increased intestinal permeability. By antagonizing zonulin signaling and restoring epithelial integrity, Larazotide is explored for:

Reduction of intestinal permeability ("leaky gut")
Downregulation of systemic and gut-associated inflammation
Prevention of antigenic and microbial translocation
Adjunctive treatment for autoimmune, neurologic, dermatologic, and metabolic disorders linked to GI barrier dysfunction

2. Mechanisms of Action

2.1 Zonulin Pathway Antagonism

Zonulin modulates tight junction permeability. Elevated zonulin signaling contributes to tight junction disassembly, increased intestinal permeability, translocation of antigens/endotoxins (LPS)/pathogens, systemic inflammation, and autoimmune disease progression. Larazotide antagonizes zonulin-mediated signaling.

2.2 Barrier Restoration

Clinical benefits: Enhanced intestinal epithelial barrier integrity · Prevention of claudin and occludin protein disassembly · Reduced paracellular permeability · Restored mucosal homeostasis

Barrier restoration prevents endotoxin (LPS) passage into systemic circulation, antigenic protein translocation, microbial/pathogen entry, and immune system activation from gut-derived signals.

2.3 Anti-Inflammatory Actions

Reduced translocation produces: downregulated pro-inflammatory cytokines (IL-6, TNF-α, IL-1β), decreased systemic inflammation, reduced autoimmune trigger activation, improved gut-brain, gut-skin, and gut-immune axis homeostasis.

2.4 Key Advantage

No Systemic Immunosuppression: Larazotide works locally in the GI tract without systemic hormonal or immunosuppressive activity, making it well-suited for long-term adjunctive use in chronic conditions.

2.5 Synergy With Other Peptides

With BPC-157: Larazotide restores tight junctions → BPC-157 promotes mucosal healing. Comprehensive gut barrier repair with synergistic anti-inflammatory action.

With KPV: KPV provides NF-κB inhibition and cytokine modulation while Larazotide addresses barrier dysfunction. Dual-mechanism inflammation control.

With Glutathione / NAD+: Redox support for gut lining oxidative stress with enhanced cellular repair alongside barrier restoration.

3. Evidence Summary — Clinical Domains

3.1 Gastrointestinal Conditions

Increased Intestinal Permeability / "Leaky Gut": Primary indication with direct mechanistic targeting
Celiac Disease & Gluten Sensitivity: Prevents gluten-triggered tight junction disruption
IBS (Irritable Bowel Syndrome): Addresses permeability component of symptoms
IBD (Crohn's, Ulcerative Colitis): Adjunctive barrier support for inflammatory bowel conditions

3.2 Autoimmune & Systemic Conditions

Autoimmune Diseases: Rheumatoid arthritis, Hashimoto's thyroiditis, lupus, MS with gut-immune axis involvement
Chronic Fatigue Syndrome: Addresses systemic inflammation linked to barrier dysfunction
Fibromyalgia: Inflammatory component management

3.3 Neuroinflammation & Gut-Brain Axis

Brain fog and cognitive symptoms, mood disorders linked to gut permeability, neuroinflammatory conditions. Integrates well with Semax/Selank for neuroplasticity, BPC-157 for gut-brain axis support, NAD+ for cellular energetics.

3.4 Dermatologic & Metabolic Conditions

Psoriasis, eczema, acne with gut-skin axis involvement. Metabolic dysfunction: insulin resistance and metabolic syndrome with inflammatory components.

4. Administration Routes & Protocols

4.1 Route of Administration

Submucosal Oral (preferred): Swish and hold 60–90 seconds before swallowing
Sublingual: Hold under tongue for enhanced absorption through oral mucosa
Transnasal: Nasal spray delivery as alternative route for mucosal absorption

4.2 Reconstitution (5 mg Lyophilized Vial)

Diluent: 2 mL sterile bacteriostatic saline · Method: Gently swirl until dissolved — do NOT shake
Final Concentration: 2.5 mg/mL (0.1 mL = 0.25 mg; 0.4 mL = 1 mg)
Storage: Refrigerate (2–8°C) — use within 7–10 days

4.3 Typical Dosing

Initial Dose: 0.5 mg to 1 mg per administration · Frequency: 1–2× daily
Method: Draw 0.2–0.4 mL, swish and hold for 60–90 seconds
Timing: 15–30 minutes before meals · Cycle: 6–8 weeks on, 2–4 weeks off

5. Clinical Decision Trees

Decision Tree 1 — Protocol Selection

Leaky gut / elevated zonulin confirmed? → Larazotide 0.5–1 mg 2× daily × 6–8 weeks

Celiac / gluten sensitivity? → Larazotide 0.5 mg before meals + strict GFD

IBS/IBD with barrier dysfunction? → Larazotide + BPC-157 + KPV stack × 6–8 weeks

Autoimmune with gut-immune axis involvement? → Larazotide + immune support × 8 weeks, reassess

Neuroinflammation / brain fog? → Larazotide + Semax/Selank + BPC-157

Decision Tree 2 — Larazotide vs BPC-157 vs KPV

Primary barrier dysfunction / permeability? → Larazotide

Primary mucosal injury / ulceration? → BPC-157

Primary immune-mediated GI inflammation? → KPV

Mixed barrier + inflammation? → Larazotide + KPV

Comprehensive gut repair? → Larazotide + BPC-157 + KPV

6. Integrated Treatment Archetypes

Archetype A — Comprehensive Gut Repair

Systemic: Larazotide 0.5–1 mg 1–2× daily + BPC-157 250–500 mcg oral/SC daily + KPV 200–500 mcg oral daily

Outcome: Comprehensive gut barrier restoration with multi-pathway support.

Archetype B — Autoimmune Support

Systemic: Larazotide 1 mg 2× daily + Thymosin Alpha-1 per immune protocol + Glutathione 200–500 mg daily

Lifestyle: Anti-inflammatory diet, stress management, sleep optimization

Archetype C — Gut-Brain Axis

Systemic: Larazotide 0.5–1 mg daily + BPC-157 250 mcg SC daily + Semax or Selank per neuroplasticity protocol + NAD+ weekly

Outcome: Improved cognitive clarity, reduced neuroinflammation, enhanced gut-brain communication.

Archetype D — Post-Antibiotic / Dysbiosis Recovery

Systemic: Larazotide 0.5 mg 2× daily + BPC-157 250 mcg oral daily + KPV 250 mcg oral daily

Adjuncts: Probiotics, prebiotic fiber, bone broth

7. Expected Clinical Timeline

Week 1–2: Initial GI symptom improvement, reduced bloating
Week 3–4: Decreased inflammatory markers, improved digestion
Week 6–8: Measurable barrier restoration, autoimmune flare reduction

8. Contraindications, Adverse Effects & Monitoring

Contraindications

Active GI ulceration (theoretical caution)
Severely immunocompromised patients (limited data)
Pregnancy / lactation (insufficient data)
Known hypersensitivity to peptide components

Safety Profile

Clinical trials have demonstrated safety at doses up to 12 mg/day orally with minimal adverse effects. No systemic hormonal or immunosuppressive activity. Local GI action with minimal systemic absorption.

Monitoring

GI symptom tracking (bloating, discomfort, bowel patterns)
Zonulin levels (if available)
Inflammatory markers (CRP, ESR)
Autoimmune disease activity markers
Subjective well-being and energy levels

Legal Disclaimer

This document is provided solely for educational and informational purposes. Larazotide (AT-1001) and other peptides referenced herein are not FDA-approved drugs. Their clinical use may constitute off-label or investigational use. Peptide Protocol Portal makes no representations or warranties. Clinical decisions remain the sole responsibility of the licensed practitioner. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable for any damages or adverse outcomes. Use at your own risk.

References — Larazotide Acetate (AT-1001) Clinical Reference Guide

Clinical Trials & Efficacy

1. Leffler DA, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology, 148(7), 1311-1319 (2015).

2. Kelly CP, et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Alimentary Pharmacology & Therapeutics, 37(2), 252-262 (2013).

3. Paterson BM, et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Alimentary Pharmacology & Therapeutics, 26(5), 757-766 (2007).

Zonulin & Intestinal Permeability

4. Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiological Reviews, 91(1), 151-175 (2012).

5. Lammers KM, et al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology, 135(1), 194-204 (2008).